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Abstract
Since the first report that intensive insulin therapy reduced
mortality in selected surgical critically ill patients, lowering of blood
glucose levels has been recommended as a means of improving
patient outcomes. In this initial Leuven trial, blood glucose control
by protocol using insulin was applied to 98.7% of patients in the
intensive group but to only 39.2% (P <0.0001) of patients in the
control group. If appropriately applied, such protocols should
decrease both the mean blood glucose concentration and its
variability (variation of blood glucose concentration). Thus, it is
logically possible that the benefit of intensive insulin therapy in the
first Leuven trial was due to a decrease in mean glucose levels, a
decrease in their variability, or both. Several recent studies have
confirmed significant associations between variability of blood
glucose levels and patient outcomes. Decreasing the variability of
blood glucose levels might be an important dimension of glucose
management, a possible mechanism by which an intensive insulin
protocol exerts its putative beneficial effects, and an important goal
of glucose management in the intensive care unit. Clinicians need
to be aware of this controversy when considering the application of
intensive insulin therapy and interpreting future trials.
Intensive insulin therapy
Acute hyperglycemia associated with insulin resistance is
common in critically ill patients [1,2], and control of blood
glucose levels is considered important [3-6]. In the Leuven I
trial, intensive insulin therapy (IIT) (target blood glucose levels
of 4.4 to 6.1 mmol/L) was reported to reduce mortality in
selected surgical patients compared with conventional
glycemic control (P <0.04) (mean blood glucose level of
8.5 mmol/L) [7]. In the Leuven II trial of medical critically ill
patients, IIT failed to achieve a significant reduction in
mortality on intention-to-treat analysis (P = 0.31) (Table 1) [8].
Using the pooled dataset of these two randomized controlled
trials, IIT was associated with a reduction in mortality from
23.6% to 20.4% (P = 0.04). Furthermore, compared with a
blood glucose level of 110 to 150 mg/dL, mortality was
higher with a blood glucose level of greater than 150 mg/dL
(odds ratio = 1.38; P = 0.007) and lower with a level of less
than 110 mg/dL (odds ratio = 0.77; P = 0.02) [9]. Subse-
quent investigations suggested that metabolic control, as
reflected by normoglycemia, rather than any other effect of
insulin was responsible for this effect [10]. Recently, lowering
blood glucose levels has been recommended in international
consensus guidelines as a means of improving patient
outcomes [11,12]. However, in a multicenter randomized
control trial among septic patients (VISEP [Efficacy of Volume
Substitution and Insulin Therapy in Severe Sepsis] study), IIT
had no significant effect on mortality (P = 0.74) [13]
(Table 1). A recently published meta-analysis has also shown
that, in critically ill adult patients, IIT is not associated with a
significant reduction in hospital mortality but is clearly
associated with an increased risk of hypoglycemia [14].
Variability of glycemia in critically illness
Blood glucose levels in critically ill patients vary markedly,
even when using continuous feeding and insulin infusions
[15]. Variability of glycemia is expressed as the magnitude of
the fluctuation in glycemic control [16]. Even in the presence
of the same mean value, the nature of glycemic control can
be quite different in terms of variability (Figure 1a,b).
In three recently published IIT trials, an insulin protocol was
applied to most of the patients in the IIT groups (about 98%)
(Table 1). If appropriately applied, such protocols should
decrease both the mean blood glucose concentration and its
variability. Contrary to this, there was no specific insulin
protocol for patients in the control groups of such trials until
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glycemia exceeded 11.1 or 11.9 mmol/L. In this setting, 61%,
30%, and 26% of patients in the conventional treatment arm
did not appear to receive any protocol-based glycemic
control in the Leuven I, Leuven II, and VISEP trials, respec-
tively (Table 1). Such lack of protocol-based care might be
logically expected to increase glycemic variability (Figure 1a)
[15]. The rest of the conventional group patients who
received an insulin protocol targeting a glycemia of between
10 and 11.1 mmol/L might have had a higher mean blood
glucose concentration but less variability in glycemia
(Figure 1b).
The Leuven I trial (surgical intensive care unit [ICU]) is
currently the only study in which IIT reduced 28-day mortality
on intention-to-treat analysis [7]. Interestingly, in the Leuven I
study, the proportion of patients who were treated without
the application of any glycemic control protocol was signifi-
cantly higher compared with the other two major randomized
trials of IIT (P <0.0001). It is therefore possible that more
Leuven I patients in the conventional treatment group had a
greater degree of variability compared with the two later
studies. This may explain why the dramatic results of the
Leuven I study were not subsequently reproduced in other
trials. Therefore, assessment of the variability of blood
glucose levels might be necessary to fully understand the
divergent results of these trials.
Evidence that blood glucose variability
affects outcome
In 2006, we published the first study to assess the impact of
variability of glycemia in critically ill patients. In this four-center
retrospective study of 7,049 critically ill patients, we found
that glycemic variability was an important dimension of
glycemic control [16]. We used the standard deviation and
the coefficient of variation of glycemia as markers of glycemic
variability. We found that such variability was independently
associated with ICU and hospital mortality rates as well as
length of ICU stay. Most importantly, we found that glycemic
variability predicted outcome better than mean blood glucose
levels did.
Following our study, five other groups have also assessed the
possible effect of variability of glycemia. In a single-center
retrospective study of septic patients hospitalized for more
than 1 day, Ali and colleagues [17] found, in a multivariate
logistic regression analysis, that patients with an increased
glycemic lability index, but lower average glucose values, had
an increased risk of hospital mortality (odds ratio = 4.73)
compared with those with lower glycemic lability. These
associations were not observed in patients with a high mean
glucose level [17]. Hirshberg and colleagues [18] assessed
the association of the variability of glycemia with mortality and
morbidity in critically ill children admitted for more than 1 day
in a pediatric ICU. The authors defined variability of glycemia
as occurring in patients who experienced both hyperglycemia
(blood glucose of greater than 8.4 mmol/L) and hypoglycemia
Table 1
Glycemia and mortality in three randomized controlled trials to assess the benefit of intensive insulin therapy
Glycemic control, mmol/La Insulin protocol application Mortality
Conventional IIT Conventional IIT Conventional IIT P value
Leuven I trial [7] 8.5 ± 1.8 5.7 ± 1.1 307/783  755/765  63/783  35/765 
(39.2%) (98.7%) (8.0%) (4.6%) <0.04
Leuven II trial [8] 8.5 ± 1.7 6.2 ± 1.6 426/605  580/595  162/605  144/595  0.31
(70%) (98%) (26.8%) (24.2%)
VISEP study [13] 8.4 ± 1.8 6.2 ± 1.0 215/290  243/247  75/289  61/247  0.74
(74.1%) (98.4%) (26.0%) (24.7%)
aGlycemic control values are presented as mean ± standard deviation. IIT, intensive insulin therapy; VISEP, Efficacy of Volume Substitution and
Insulin Therapy in Severe Sepsis.
Figure 1
Graphic representations of glycemic control with a high mean glucose
level and high (a) or low (b) variability.(blood glucose of less than 3.4 mmol/L) during ICU stay. In
this single-center retrospective study, increased variability
was significantly associated with increased mortality, noso-
comial infections, and hospital length of stay [18]. Dossett
and colleagues [19] assessed the impact of glycemic
variability on mortality in patients admitted to a surgical ICU.
In this single-center retrospective study, standard deviation,
percentile values, successive changes in blood glucose, and
the triangular index (calculated by dividing the maximum
sample density distribution of each histogram by the total
number of each measurement) for various glucose-related
indices were used as markers of glycemic variability. On uni-
variate analysis, increased variability in glycemia was asso-
ciated with increased mortality, whereas mean blood glucose
concentration was not [19]. Waeschle and colleagues [20]
assessed the relationship between glycemic variability and
mortality in septic patients. In this single-center prospective
study, standard deviations of blood glucose levels were used
as markers of glycemic variability. A standard deviation of
blood glucose levels of above 20 mg/dL was associated with
a 9.6-fold increase of mortality compared with those with less
than 20 mg/dL. All patients with severe sepsis and septic
shock who died had a standard deviation of blood glucose
levels of above 20 mg/dL [20]. In a single-center retro-
spective observational study, Krinsley [21] found that
mortality among patients with the lowest quartile of standard
deviation of glucose levels, a surrogate of glycemic variability,
was 12.1%, increasing to 19.9%, 27.7%, and 37.8% in the
second, third, and fourth quartiles, respectively. The
relationship between glycemic variability and mortality was
strongest when mean blood glucose level was in the
euglycemic range (70 to 99 mg/dL). In this range, mortality in
patients with high glycemic variability (fourth quartile with
mortality of 30.1%) was 5.1 times greater than in patients
with low glycemic variability (first quartile with mortality of
5.9%) [21]. Thus, all studies so far have confirmed that vari-
ability is associated with increased mortality and no studies
have refuted this association.
Possible glycemic variability indices in the
critically ill
So far, the standard deviation of glycemia [16,18,20,21], the
coefficient of variation of glycemia [16], the glycemic lability
index [17], the percentile values for glycemia [19], successive
changes in blood glucose [19], and the triangular index [19]
have all been used as indices for variability of blood glucose
levels during ICU stay. There are other possible measures for
variability of glycemia which are used mainly in the chronic
setting during management of diabetes. For example, the
mean amplitude of glycemic excursion (MAGE) has been
widely used as a glycemic variability index in diabetic patients
[22]. MAGE is calculated as the arithmetic mean of blood
glucose increases or decreases when both ascending and
descending variations exceed the value of standard deviation
of the blood glucose concentration in 24 hours. However,
MAGE estimation requires the use of continuous glucose
sensors [23] and is only suitable for assessment for patients
with large variability. The incremental area under the curve
above mean pre-prandial glucose values (AUCpp) have also
been used in diabetic patients. The AUCpp has been used
only in patients with intermittent parenteral feeding [24]. Thus,
it is not suitable for critically ill patients requiring continuous
enteral and/or parenteral feeding. The mean of the daily
difference in glucose (MODD) is the absolute difference in
mean blood glucose control during 24 hours [25]. MODD was
measured using continuous glucose sensors and was used as
an assessment tool for inter-day variability. Thus, it is also not
suitable for the assessment of intra-day glycemic variability.
Only one study has compared the predictive value of several
blood glucose indices. Ali and colleagues [17] calculated the
standard deviation of glucose, the MAGEs, and the glycemic
lability index. They found that the glycemic lability index had
the best discrimination for mortality (area under the curve =
0.67; P <0.001) [17]. More studies are required to determine
the best surrogate of glycemic variability in the ICU.
Why is glycemic variability associated with
worse outcomes?
There are at least four possible explanations for the asso-
ciation between glycemic variability and outcome which we
and others have observed. First, less glycemic variability may
reflect more attention to detail in medical and nursing care,
which may be the real determinants of better outcomes.
Second, less glycemic variability may be associated with less
severe illness. Third, glycemic variability might have a true
deleterious biological effect in critically ill patients. Fourth, any
combination of the above factors might apply.
There are studies to support the hypothesis that variations in
glucose levels might have biological toxicity. Quagliaro and
colleagues [26] have shown that, in umbilical vein cells,
protein kinase C-beta, a surrogate of oxidative stress, was
higher in the presence of fluctuations from hyperglycemia to
normoglycemia when compared with sustained hypergly-
cemia. Monnier and colleagues [27] have shown that gly-
cemic variability might trigger adverse biological events and
oxidative stress in patients with type II diabetes. Such
increased oxidative stress can result in endothelial dys-
function and contribute to vascular damage by triggering one
of at least four major pathways: (a) enhanced polyol activity,
causing sorbitol and fructose accumulation; (b) increased
formation of advanced glycation end products; (c) activation
of protein kinase C and nuclear factor-kappa-B; and (d)
increased hexosamine pathway flux [28,29]. Furthermore,
Watada and colleagues [30] and Azuma and colleagues [31]
have shown that large glycemic variability enhances
monocyte adhesion to endothelial cells in rats. Risso and
colleagues [32] have shown that rapidly changing from
hyperglycemia to normoglycemia causes increased apoptosis
of human umbilical vein cells when compared with sustained
hyperglycemia.
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The NICE-SUGAR (Normoglycemia in Intensive Care
Evaluation-Survival Using Glucose Algorithm Regulation) trial
is a large (n = 6,100) multicenter randomized controlled study
of ITT [33] that has just completed recruitment. As the NICE-
SUGAR trial compared two groups with a similar spread of
target blood glucose values (IIT: 4.5 to 6.1 mmol/L versus
control: 8 to 10 mmol/L), this trial should make it possible to
test the benefit of lowering the mean blood glucose
concentration in a manner largely independent of the effects
of IIT on glycemic variability. If there is a benefit from IIT, it
would confirm that lowering the mean glucose level toward
normoglycemia is a major mechanism behind the putative
beneficial effects of IIT. If there is no difference in the
outcomes of the ITT and control groups in NICE-SUGAR, it
may be either that IIT is not effective or alternatively that, once
glycemic variability is equivalent in both groups, the apparent
beneficial effect of reducing mean blood glucose levels
disappears. If IIT is shown to cause harm, it may be that, once
variability is similarly reduced by having protocol-based care
in both groups, the harmful effects of hypoglycemia become
evident. The importance of understanding the mechanisms
involved is great. If reducing variability of glycemia is the
major biological mechanism underlying the putative benefit of
IIT, it would not be necessary to intensively lower glucose
levels (with the attending risk of hypoglycemia).
Conclusions
Tight glucose control might logically have one of two
meanings: ‘decreasing mean blood glucose concentrations’
or ‘decreasing variability in glycemia’. Decreasing the
variability of blood glucose concentration might be an
important dimension of glucose management, a possible
mechanism by which applying the intensive insulin protocol
exerted its putative beneficial effects, and an important goal
of glucose management in the ICU. Clinicians need to be
aware of this controversy when considering the application of
IIT and interpreting future trials.
Note
This manuscript was submitted in early November 2008 prior
to any knowledge of the NICE-SUGAR trial results, which
were released by the New England Journal of Medicine on
March 24, 2009. The authors note the following facts: the
standard deviation (typical measure of variability) of glycemia
in the IIT and Conventional treatment groups were essentially
the same (25 versus 26 mg/dL) while 206 patients in the IIT
group experienced severe hypoglycemia compared to 15 in
the conventional treatment group. Mortality was greater in the
IIT group.
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